For a 62-year-old with symptomatic CAD on maximal statin therapy and a CAC score of 280, is a single 180-patient RCT showing slowed CAC progression on a surrogate endpoint sufficient to recommend MK-7 360µg daily now — given its benign safety profile and low cost — or does the paradox that statins themselves increase CAC while reducing events mean CAC slowing is uninterpretable as a benefit signal without hard-outcome data?
Heat
Resolution
No fixed date yet
Sources
0
How this gets settled
⤢
Resolving trial — not yet identified
Resolution
No fixed date yet
The debate
⤢
Camps not yet extracted — awaiting next scan
Who could settle it
⤢
Know an expert who could settle this? Suggest one →
Get involved
Preview⤢
Not yet tracked
WatchSteer thisSoon
Sources & verification
⤢
1linked & dated sources
VerifiedConfirmed against a primary source (registry API or dual-model citation gate).EstimateA computed estimate (e.g. comparable-based cost or modeled range), not a measured value.Scan-reportedReported by the scan and linked to its source — not yet independently verified.
For a 62-year-old with symptomatic CAD on maximal statin therapy and a CAC score of 280, is a single 180-patient RCT showing slowed CAC progression on a surrogate endpoint sufficient to recommend MK-7 360µg daily now — given its benign safety profile and low cost — or does the paradox that statins themselves increase CAC while reducing events mean CAC slowing is uninterpretable as a benefit signal without hard-outcome data? | Synapse Debates